2024-519129-38-00招募中2 期
Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)
Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb5 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2025年1月13日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 5
- 主要终点
- To investigate the behavior of exhausted CD8+ T in response to pembrolizumab in TCs and the relationships between T cell clusters. To this aim, “spatial-transcriptomic” sequencing will be performed in tumor tissues and will be paired to single-cell maps at peripheral level before and after pembrolizumab.
研究概览
简要总结
Activity of pembrolizumab as neoadjuvant treatment in high-risk TCs
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of differentiated thyroid carcinoma candidate to surgery not previously treated will be enrolled in this study
- •A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3.b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 4 months after the last dose of study treatment.
- •Patients with a risk > 20% for persistent/recurrent disease (Filetti S, 2019; Haughen BR 2017): primary tumor > 4 cm; multifocal papillary microcarcinoma with extra tumor extension (ETE) and known BRAF V600E mutation; clinical N1; gross ETE (macroscopic invasion of perithyroidal soft tissues); extranodal extension; expected incomplete tumour resection
- •Poorly differentiated carcinoma; Hurtle cell carcinoma
- •Patients with distant metastasis at diagnosis
- •The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
- •Have measurable disease based on RECIST 1.
- •Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Evaluation of ECOG is to be performed within 7 days prior to the date of allocation/randomization
- •Have adequate organ function as defined in the following table (Table 2) Specimens must be collected within 10 days prior to the start of study treatment.
- •Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 6 months (e.g. 5 terminal half-lives for pembrolizumab) after the last dose of study treatment and refrain from donating sperm during this period.
排除标准
- •A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization (see Appendix 3). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
- •Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed
- •Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- •Has an active infection requiring systemic therapy
- •History of Human Immunodeficiency Virus (HIV) infection.
- •History of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority
- •Has a known history of active TB (Bacillus Tuberculosis).
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
- •Has had an allogenic tissue/solid organ transplant.
- •Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to randomization
- •Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
- •Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Administration of killed vaccines is allowed.
- •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ (eg, breast carcinoma or cervical cancer in situ that have undergone potentially curative therapy are not excluded).
- •Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention
结局指标
主要结局
To investigate the behavior of exhausted CD8+ T in response to pembrolizumab in TCs and the relationships between T cell clusters. To this aim, “spatial-transcriptomic” sequencing will be performed in tumor tissues and will be paired to single-cell maps at peripheral level before and after pembrolizumab.
To investigate the behavior of exhausted CD8+ T in response to pembrolizumab in TCs and the relationships between T cell clusters. To this aim, “spatial-transcriptomic” sequencing will be performed in tumor tissues and will be paired to single-cell maps at peripheral level before and after pembrolizumab.
次要结局
- Cancer immunotherapy aims to induce a durable human immune response in order to destroy tumour cells (Jacobson M, 2019). Biological mechanisms behind a prolonged immune response are still unknown. We hypothesize that the persistence of tumor-specific T-cell clones after the treatment of primary cancer, might contribute to a durable immune response as well as a better patients’ outcome. Single cell/spatial-transcriptomics sequencing will be applied to the blood samples collected after surgery and
研究者
Laura Locati
Scientific
Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
研究点 (5)
Loading locations...
相似试验
招募中
2 期
Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSino2023-505917-25-00Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb28
招募中
2 期
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45
尚未招募
2 期
Pembrolizumab + MRGOO3 as Neoadjuvant in NPCNPCNCT07267338Union Hospital, Tongji Medical College, Huazhong University of Science and Technology35
招募中
不适用
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaNCT07268131Fudan University30
招募中
2 期
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat CancerOropharyngeal CancerNCT07290621University of Chicago30